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S U M M A R Y
Background: Infection is a common epiphenomenon of advanced diabetic foot disease and the most
common reason for diabetes-related hospitalizations and lower extremity amputations. Major advances
have been made in the past three decades in our understanding and management of diabetic foot
infections (DFIs). The optimal treatment of DFIs clearly involves multidisciplinary input.
Methods: A comprehensive search of the literature on DFIs from January 1960 through June 2015 was
performed, with an emphasis on information published in the past 30 years.
Results: There have been many new insights into the microbiology, diagnosis, and treatment of DFIs,
although the implementation of this knowledge in clinical practice has been suboptimal. Today, the use
of evidence-based guidelines, multidisciplinary teams, and institution-speciﬁc clinical pathways helps
guide optimal care of this multifaceted problem. Patients are more often treated in the ambulatory
setting, with antibiotic regimens that are more targeted, oral and shorter course, and with more
conservative (but earlier) surgical interventions. New diagnostic and therapeutic methods are being
developed at an accelerating pace.
Conclusions: The worldwide increase in the incidence of diabetes and longer lifespan of diabetic patients
will undoubtedly increase the incidence of DFIs. Clinicians caring for diabetic patients should have an
understanding of current methods for preventing, diagnosing, and treating DFIs.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The incidence of foot infections in persons with diabetes ranges
from a lifetime risk of up to 25% in all persons with the diagnosis, to
4% yearly in patients treated in a diabetic foot center.1 Diabetic foot
infections (DFIs) occasionally present as cellulitis or post-traumatic
(including postsurgical) infections,2 but are most commonly a
consequence of ulcerations secondary to progressive peripheral
polyneuropathy. This causes a loss of protective sensation, as well as
foot deformities, gait disorders, anterior displacement of weight-
bearing during walking,3 and reduced mobility. These neurological
problems are commonly accompanied by arterial insufﬁciency and
immunological disturbances. Developing a DFI is now the most
common diabetes-related reason for hospitalization and lower
extremity amputation.4 This review aims to review the growth of* Corresponding author. Tel.: +41 22 372 33 11; fax: +41 22 372 98 02.
E-mail address: ilker.uckay@hcuge.ch (I. Uc¸kay).
http://dx.doi.org/10.1016/j.ijid.2015.09.023
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).knowledge over the past 30 years on the pathogens,5,6 radiological
diagnosis,7 and medical8,9,10 and surgical treatments of DFI.11
2. Management of diabetic foot infections: 1985 and 2015
Few of today’s clinicians appreciate how limited were the
knowledge base and therapeutic arsenal available to manage DFI
30 years ago. Although the problem was common, there were
remarkably few scientiﬁc papers published on DFIs. The major
source of clinical information was textbooks, the most compre-
hensive of which was The Diabetic Foot. The chapter on infection in
the ﬁrst edition, published in 1973, emphasized the importance of
vascular insufﬁciency and gangrene, with little discussion of
treatment, and none of the references were speciﬁcally on DFI.12
The third edition (1983) was the ﬁrst with a DFI reference,13 and it
was not until the fourth edition (1988) that there was a discussion
of wound culture techniques.14 In the mid 1980s, the general belief
was that (1) the major pathophysiological cause of DFIs was limbciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 2. Major causes of hospital discharge, by year, for diabetes-related lower
extremity conditions (in thousands), USA, 1988–2007 (http://www.cdc.gov/
diabetes/statistics, accessed 30 June 2015).
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DFIs were almost always polymicrobial, with obligate anaerobes
playing a major role; (3) nearly all patients with a DFI should be
hospitalized and treated with broad-spectrum parenteral antibi-
otic therapy; and (4) severe or apparently non-responsive
infections usually required a lower extremity amputation. We
now know that virtually all of these concepts were wrong. While
the prevalence of diabetic foot disease (especially as a cause of
hospitalization) has increased, ulcers and infection, not vascular
disease, are now the major underlying cause (Figures 1 and 2).
Progress in the understanding of diabetic foot problems
accelerated with the ﬁrst (of what are now many) diabetic foot
meeting, held in Malvern, UK in 1986. In 1987 the American Diabetes
Association (ADA) started a Foot Council, which held a symposium at
their annual meetings. In 1991 the International Working Group on
the Diabetic Foot (IWGDF) held the ﬁrst of its quadrennial meetings,
and the European Association for the Study of Diabetes founded a
Diabetic Foot Study Group (with an annual meeting) in 1998.
These scientiﬁc organizations and meetings helped trigger a
dramatic increase in the number of publications (and citations) on
DFIs (Figures 3 and 4). The growth of scientiﬁc evidence allowed
various organizations to produce guidelines for diabetic foot care,
beginning with those of the ADA and IWGDF in the late 1990s. One of
the major achievements in the last 30 years was the recognition of
the value of a multidisciplinary approach to this complex problem,15
which led to the opening of specialized diabetic foot centres all over
the world. Unfortunately, the implementation and translation of this
knowledge into therapeutic success has been more limited. While
some centres have improved various parameters of DFI care, many,
especially in resource-poor countries, have not. Table 1 summarizes
the authors’ views on the major changes in our understanding of, and
approach to, DFIs since 1985.
3. International recommendations, guidelines, and
classiﬁcations
There has been a proliferation of guidelines, checklists, and
classiﬁcation schemes regarding DFIs in the last 30 years. The ﬁrstFigure 1. Number of hospital discharges, by year, for diabetes-related lower
extremity conditions (in thousands), USA, 1988–2007 (http://www.cdc.gov/
diabetes/statistics, accessed 30 June 2015).guidelines speciﬁcally devoted to DFI, both published in 2004,
were those commissioned by the Infectious Diseases Society of
America (IDSA) and by the IWGDF. These have been updated,16–18
and we refer readers interested in the literature regarding
deﬁnitions, classiﬁcations, differential diagnoses of infection,19
and guidelines to other literature to our prior publications.8,20
4. Pathogens
Starting in the late 1970s, studies demonstrated that aerobic
Gram-positive cocci (especially Staphylococcus aureus), often as
monomicrobial infections, were the predominant pathogens in
DFIs, with aerobic Gram-negative rods found mostly in patientsFigure 3. Published items per year located with the search term ‘‘diabetic foot
infection’’ in Web of Science.
Figure 4. Number of citations per year for published papers located with the search
term ‘‘diabetic foot infection’’ in Web of Science.
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caused by multidrug-resistant organisms, such as extended-
spectrum beta-lactamase-producing Gram-negative rods21 or
methicillin-resistant S. aureus (MRSA), have emerged as a
substantial problem. Infection with an antibiotic-resistant organ-
ism certainly requires the selection of an agent active against that
isolate, but should not otherwise alter therapeutic management.22
Studies of outcomes of DFIs caused by multi-resistant pathogens
compared with other organisms have produced conﬂicting results,
with some ﬁnding no worse outcomes,23,24 while others have.25 InTable 1
Key changes in the knowledge and management of diabetic foot infections in the last 
Research ﬁeld 1985 
Pathogens Methicillin-susceptible Staphylococcus aureus,
streptococci, Enterobacteriaceae
Microbiological diagnosis Standard cultures, usually of swab specimens 
Imaging Plain X-rays; scintigraphy (bone, leukocyte scan
Antibiotic agents Penicillins; 1st to 3rd generation cephalosporin
some 2nd generation ﬂuoroquinolones
Route of administration
and site of treatment
Initial (sometimes prolonged) intravenous
administration, usually in hospital
Spectrum of antibiotic therapy Relatively broad (directed at Gram-positive an
Gram-negative pathogens)
Duration of antibiotic therapy Many weeks for soft tissue infections; 6–12
weeks for bone
Surgical approach Aggressive (ablative) therapeutic surgery;
inpatient treatment
Revascularization Open vascular surgery 
Management
guidelines
Mostly individual, empirical approaches
Individual recommendations and practices on th
hospital level
Adjunctive treatments Stimulation with growth factors; platelet-rich
products; larval biotherapy (maggots)
Dressing Simple dressings, with separate use of
disinfection agents
Scientiﬁc publications Mostly case series 
ESBL, extended-spectrum beta-lactamase; MRI, magnetic resonance imaging; MRSA, m
computed tomography; SPECT/CT, single photon emission computed tomography/coma previous study, we found that among 48 papers published
between 1999 and 2013, only ﬁve attempted a comparison of
outcomes between DFIs caused by MRSA and those caused by other
pathogens.5 Overall, there were no clear differences in outcomes,
but many trials failed to adjust for case-mix, or to seek a
relationship between microbiology and outcomes. Notwithstand-
ing the limitations of the available literature, we do not believe
there is a need for any special treatment (other than selecting an
active antibiotic agent) for DFIs caused by MRSA.5
Until the most recent decade, the majority of studies on the
microbiology of DFI were conducted in North America and Europe.
In recent years, investigations in warm climates (especially India,
but also the Middle East and Africa) have found the most common
isolates to be Gram-negative rods, particularly Pseudomonas
aeruginosa. We can only speculate on the reasons for this disparity,
but they may include a hot climate causing foot sweating, the use
of poor footwear, a high incidence of patient self-treatment with
antimicrobials, frequent foot washing, and suboptimal perineal/
hand hygiene.8 Thus, clinicians in these regions should consider
covering Enterobacteriaceae and Pseudomonas spp, pending culture
and sensitivity results.
When treating DFIs, clinicians have frequently added antibiotic
agents that are speciﬁcally directed against obligate anaerobic
bacteria, especially when the wound is gangrenous or has a fetid
odour. However, our recent literature review of DFI studies
revealed that anaerobes were infrequent isolates, were not
associated with any speciﬁc clinical ﬁndings, and did not clearly
lead to more severe manifestations.6 Bacteroides and Peptostrepto-
coccus have been the two main species reported, but it is uncertain
if they are pathogens or colonizers associated with the presence of
a greater degree of tissue ischemia or necrosis. Most clinical trials
of antimicrobial therapy for DFI have not employed adequate
methods to culture anaerobic organisms. One randomized trial30 years—summary of the authors’ views
2015
More multidrug-resistant organisms (MRSA, ESBLs)
Predominance of Gram-negative pathogens in (sub)tropical climates
Aerobic and anaerobic cultures of tissue specimens (soft tissue and bone)
Molecular microbiology (e.g., PCR)
Metagenomics
s) MRI; SPECT/CT; PET/CT
s; 4th/5th generation cephalosporins; carbapenems; 3rd/4th generation
ﬂuoroquinolones; linezolid; daptomycin
Mostly oral (sometimes after a brief intravenous course), even in the
presence of vascular disease or osteomyelitis; some topical; outpatient
except for severe infections or complex treatments
d Very broad empiric therapy for severe infections; more targeted for mild/
moderate infections and for deﬁnitive therapy
1–2 weeks for soft tissue infections; 4–6 weeks for osteomyelitis
More conservative (tissue sparing) therapeutic (even for osteomyelitis)
and preventive surgery; corrective surgery;
often in outpatient facilities and specialized diabetic foot centres
More percutaneous angioplasty and distal bypasses, including
infragenicular
e
Clinical guidelines based on systematic reviews; multidisciplinary
teams, especially including podiatry; clinical pathways; some
behavioural sciences
national guidelines; validation of guidelines
Hyperbaric oxygen therapy; granulocyte-stimulating factors; research in
stem cell and bacteriophage therapies; microbiome concepts
More hydroﬁbre and silver-containing dressings; studies with topical
antibiotics embedded in dressings
More prospective randomized trials, multicenter studies, and evidence-
based (Cochrane) meta-analyses
ethicillin-resistant Staphylococcus aureus; PET/CT, positron emission tomography/
puted tomography.
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among six groups (i.e., Gram-positive anaerobic cocci, Peptos-
treptococcus magnus, Peptostreptococcus asaccharolyticus, Gram-
positive anaerobic bacilli, Gram-negative anaerobic bacilli, and
Gram-negative anaerobic coccobacilli, including here Bacteroides
spp), none was associated with worse outcomes.26 Several
randomized trials of DFIs, including soft tissue or osteomyelitis
cases, have reported similar clinical success rates when comparing
regimens with similar anaerobic spectra,27,28 and equivalent
outcomes with drugs that have broad anaerobic coverage
compared to those with a narrower spectrum.29–31 Finally, local
mycobacterial infections or tetanus are rare causes of DFI.32
4.1. Microbiome and metagenomics
Standard culture methods, which have changed little in
150 years, are limited by taking several days to complete, being
falsely negative in patients receiving antibiotic therapy, and failing
to identify many fastidious bacteria. Newer molecular techniques,
such as 16S PCR and gene sequencing, typically identify a greater
number and variety of bacteria, particularly anaerobes.33 Meta-
genomic studies have revealed interplay among bacterial commu-
nities in various environments, including wounds, that produce
speciﬁc clinical ‘syndromes’33–35 or phenotypic diseases. This
recent and rapidly emerging research area may provide more
insights into the potential association of the skin (and gastroin-
testinal) microbiome with DFI.33
5. Treatment
5.1. Podiatric care
Most patients with a DFI require some form of podiatric care,
along with medical, surgical, nursing, and physiotherapeutic
interventions.20 The increasing availability of podiatrists in many
countries appears to have led to major advances in diabetic foot
care, although robust evidence for this is pending.36 Podiatric care
is particularly aimed at preventing foot complications and includes
debridement of callus37 and necrotic tissue, nail care (especially
with onychomycosis), the treatment of blisters, prescribing proper
footwear, and ﬁtting orthotic devices. Once complications occur,
however, the goal becomes avoiding amputation.
5.2. Systemic antimicrobial therapy
Systemic antibiotic therapy is always necessary for the
treatment of clinically infected wounds, but is often insufﬁcient
to cure moderate to severe DFIs.16 This systemic therapy must
often be combined with one or more surgical procedures, pressure
off-loading, appropriate wound care, and in some cases, arterial
revascularization. With a few exceptions,38 almost all of the
currently used antimicrobial classes (if not the current genera-
tions) were available 30 years ago. What has changed is our
awareness of the need to reduce the spectrum and duration of
antibiotherapy to try to slow the tide of antibiotic resistance. While
initial antibiotic therapy for most patients must be selected
empirically, it should largely be based on the assessment of
infection severity12 and knowledge of the local microbial
epidemiology. In most regions of the world, the antibiotic regimen
should always cover S. aureus, but it may be broadened to include
Gram-negative isolates in severe infections or if the patient has
failed to respond to prior narrower-spectrum therapy. Of note, DFIs
can develop rapidly,39 making early follow-up after starting
therapy imperative. Necrotizing soft tissue infections of the
diabetic foot, including gas gangrene, are uncommon and areusually caused by mixed aerobic (and sometimes anaerobic)
bacteria rather than Clostridium species.40
Deﬁnitive antibiotic therapy should be based on culture and
sensitivity results. Even if cultures yield multiple organisms, it may
be sufﬁcient to treat only the likeliest pathogens, such as S. aureus,
streptococci, and Enterobacteriaceae. Skin commensals such as
coagulase-negative staphylococci, corynebacteria, or Bacillus spp,
and low-virulence organisms such as enterococci, can usually be
ignored unless cultured from deep, aseptically collected tissue or
infections involving osteosynthetic material or hardware. Like-
wise, the mere presence of skin or mucosal colonization with
healthcare-associated MRSA does not oblige the clinician to
empirically cover this organism,40,41 even in the presence of
underlying osteosynthetic material.42 Quantitative cultures, which
were in vogue in the past, are now rarely done as they are difﬁcult
to perform, expensive, and do not add much to deciding which
wounds are infected or what organisms to treat.35,43,44
Because most DFIs occur in the setting of peripheral arterial
disease, some have raised concerns about how well various
antibiotic agents penetrate the infected site, especially bone. This
has led many clinicians to prescribe weeks of intravenous
antibiotic therapy. The current availability of highly bioavailable
oral antibiotics, as well as the acquisition of further evidence of the
efﬁcacy of oral antibiotic regimens, has helped change this
practice. When prescribed at standard doses, most beta-lactam
antibiotics achieve relatively low (albeit therapeutic) tissue levels,
as these are time-dependent (not concentration-dependent) drugs.
Clindamycin, ﬂuoroquinolones, linezolid, rifampicin, and to some
degree, tetracyclines and co-trimoxazole, have good oral bioavail-
ability and penetration in bone, synovia, bioﬁlm, and necrotic
tissue.8 Few data support the need for parenteral therapy,45 and
studies are currently underway to compare outcomes of oral
versus intravenous therapy for complex musculoskeletal infec-
tions, including DFI. Likewise, in a retrospective analysis of more
than 2000 episodes of orthopaedic infection, including DFI, we
found no evidence of superiority of bactericidal agents over
bacteriostatic agents.46 Similarly, published randomized con-
trolled DFI trials have failed to show superiority of any particular
antibiotic agent or route of administration.8 Several systematic
reviews of antimicrobial treatments for DFI have concluded that
there is insufﬁcient evidence to recommend any particular
antimicrobial agent or route of administration.47–49
5.3. Osteomyelitis: diagnosis and therapy
DFIs generally begin when a break in the protective skin barrier
allows pathogens to multiply in the soft tissues. Diabetic foot
osteomyelitis usually occurs by the contiguous spread of infection
from overlying soft tissue. Osteomyelitis is found in up to 15% of
patients with a clinically uninfected diabetic foot ulcer; among
those with a DFI, however, approximately 20% seen in the
outpatient setting and two-thirds who are hospitalized have
infected bone at presentation.8 Diagnosing osteomyelitis of the
diabetic foot can be difﬁcult, especially early in the course. Clinical
ﬁndings suggesting infection include a deep chronic ulcer over a
bony prominence, ‘sausage toe’ (red, warm, swollen) appearance,
and an erythrocyte sedimentation rate >70 mm/h. The only
virtually pathognomonic clinical sign is the presence of fragments
of bone discharging from a wound. The probe-to-bone test is
helpful in diagnosing diabetic foot osteomyelitis if it is correctly
performed (with a blunt metal probe) and interpreted (with
consideration of the pre-test probability of osteomyelitis). Based
on several reports, the sensitivity ranges from about 60% to 87%,
speciﬁcity from 85% to 91%, and positive predictive value from 87%
to 90%, but the negative predictive value is only 56–62%.50–52 The
criterion standard for diagnosing osteomyelitis remains a culture
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Recent prospective trials have shown that culture results of soft
tissue or of needle puncture specimens of bone often fail to
correlate with transcutaneous or operative bone specimens,54 and
non-invasive diagnostic approaches for the microbiological
assessment of toe osteomyelitis should probably be abandoned.55
5.3.1. Radiological assessment of osteomyelitis
As in the past, imaging tests should generally begin with plain
X-rays. We now know that inter-observer reproducibility is poor,
especially among inexperienced clinicians,56 and early osteomye-
litis may be missed because it takes several weeks for bone lesions
to become radiologically detectable. When plain X-rays are
inconclusive, or when more detail of bone or soft tissue
abnormalities is required, magnetic resonance imaging (MRI) is
superior to the standard radionuclide studies (which have lower
speciﬁcities). Meta-analyses of the performance of three-phase
bone scintigraphy for detecting DFI using only planar imaging, or
combined with single photon emission computed tomography
(SPECT), report sensitivity of approximately 90%, but speciﬁcity of
only approximately 50%.7 Newer hybrid imaging techniques
(SPECT/CT, positron emission tomography (PET)/CT, and PET/
MRI) look to be useful, and improved radiopharmaceuticals are on
the horizon.7
5.3.2. Treatment of osteomyelitis
The past decade has provided much new information on how to
treat diabetic foot osteomyelitis. One study of 50 patients with
chronic toe osteomyelitis reported that patients who underwent
wide surgical resection had a signiﬁcantly lower relapse rate than
those who underwent less aggressive surgery.57 Contrary to the
teaching of 30 years ago, there are now reports of hundreds of cases
of diabetic foot osteomyelitis treated without surgery, with
remission rates of 60% to 70%;58,59 one recent randomized
controlled trial showed similar cure rates for medical and for
primarily surgical therapy.60 Thus, when the patient or the medical
team prefers to avoid surgery, a trial of exclusively antibiotic
therapy may be reasonable. Regarding the duration of antibiotic
therapy, a systematic review of the treatment of osteomyelitis in
patients with and without diabetes found that there was no
evidence that antibiotic therapy for more than 4–6 weeks
improves outcomes compared with this duration.61 More recently,
a small randomized controlled study found that 6 weeks compared
with 12 weeks of antibiotic treatment of diabetic foot osteomyeli-
tis produced similar results.62
5.4. Topical antibiotics, antiseptic disinfectants, and peptides
Superﬁcial, open wounds without extensive cellulitis can
potentially be treated with topical antimicrobials.9 The few
published studies of topical therapy for DFI have employed a
variety of antibiotics (e.g., mupirocin, bacitracin, neomycin,
chloramphenicol, polymyxin B, and gentamicin), as well as
antiseptics.9,63 We found no publication reporting on the use of
topical fusidic acid for DFI, an agent often misused in other types of
superﬁcial skin infection in many parts of the world.9 Studies of
topical therapy comparing an active agent to a placebo, to another
active agent, or as adjuncts to systemic antibiotic therapy, have
provided mixed results.64 In DFI, topical agents are typically
applied in mildly infected (or, inappropriately, in uninfected)
wounds, making it difﬁcult to distinguish their clinical beneﬁts
from local wound care alone. Just eradicating or reducing
microorganisms in the wound is not a sufﬁcient endpoint for
efﬁcacy,65 any more than their presence is sufﬁcient to deﬁne
clinical infection. There is no evidence that topical (or systemic)
antimicrobial therapy hastens healing of uninfected wounds, orthat it prevents clinically apparent wound infection.66,67 A pilot
randomized study of treatment in 56 DFI patients found that
adding a topical gentamicin-collagen sponge as an adjunct to
systemic antibiotic therapy (for up to 28 days), produced a higher
infection cure rate compared to systemic antibiotics alone (100%
vs. 70%, respectively) at 2 weeks after the end of therapy.63 In
another randomized trial, adding a gentamicin-collagen sponge to
systemic antibiotic therapy after a minor foot amputation in
50 patients resulted in a signiﬁcantly shorter (by almost 2 weeks)
median stump wound healing time.67 The largest study of topical
antimicrobial therapy in patients with a DFI (with 835 evaluable
patients) found that treatment with an investigational antimicro-
bial peptide cream (pexiganan) produced rates of clinical cure,
pathogen eradication, and wound healing similar to those in
patients treated with an oral ﬂuoroquinolone antibiotic (oﬂox-
acin).68 Further studies of this agent in treating mild DFI are
currently underway.
Many studies have assessed topical disinfectants or antiseptics
for the treatment of DFI, including compounds with silver,69
povidone or cadexomer iodine, or hypochlorite. The majority of
these studies used ulcer healing, rather than resolution or
prevention of infection, as the primary outcome. None of these
agents has demonstrated superior outcomes compared to non-
antiseptic dressings.8 Likewise, recent systematic reviews have
found that various other dressings, such as foam,70,71 hydrocol-
loid,72 or alginate,73 offer no advantage over other dressings for
ulcer healing or resolution of infection.8 Thus, as was true three
decades ago, dressing changes with simple gauze and saline
solution alone appears to be sufﬁcient for most patients.
5.5. Antibiotic misuse
Excessive and inappropriate uses of antibiotics have profound
negative effects, ﬁrstly for the patient, but also for the health care
system and society as a whole.9 Diabetic foot experts,74,75
including the authors of the most recent IDSA16 and IWGDF18
guidelines on DFI, the European Wound Management Association
policy document,65 and the Scottish consensus statement,76
recommend not treating clinically uninfected ulcers with antibi-
otic therapy. One double-blind, placebo-controlled trial in which
39 patients with an ‘uncomplicated’ neuropathic diabetic foot
ulcer were treated with either antibiotic therapy (oral amoxicillin–
clavulanate) or placebo found no difference in the wound healing
rates.77 Similarly, a study of patients with neuropathic (presum-
ably uninfected) foot ulcers found no signiﬁcant difference in ulcer
healing for 25 patients treated with parenteral antibiotic therapy
(ceftriaxone) compared to 25 controls not treated with anti-
biotics.78 A large registry study in Sweden showed that providing
web-based information on appropriate ulcer care was associated
with a highly signiﬁcant reduction in antibiotic prescribing for
these wounds, from 71% to 29%.79 This ﬁnding not only supports
the premise that antibiotics are not necessary in the majority of
ulcers (presumably those that are uninfected) treated with
appropriate wound care, but also that it is possible to improve
antibiotic prescribing by clinicians.
5.6. Surgery
Surgery undoubtedly plays an important role in the treatment
of many types of DFI (see Figures 5–7),80–82 but until recently there
has been limited evidence regarding what constitutes optimal
surgical treatment.83 The major aims of surgery in DFIs are to
evacuate pus, remove necrotic tissue, and minimize the risk of
further spread.80,84 Bad outcomes are often related to a delayed
diagnosis, leading to extensive destruction of the soft tissue.85
Despite a strong emphasis in recent guidelines and consensus
Figure 5. Ulcer over the ﬁrst metatarsal head: X-ray showing cortical destruction of the ﬁrst metatarsal head.
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many DFIs, it is frequently delayed, sometimes leading to
amputation.86,87 More conservative surgery for the treatment of
DFIs is now possible because we better understand the compart-
mental anatomy of the foot and the ways in which infection
spreads.88,89 Furthermore, it is clear that there are more types of
foot infection than just ‘abscesses’ and ‘diabetic gangrene’.90 We
now also appreciate that combining needed ablative foot surgery
with prompt revascularization can improve the rate of limb
salvage.91 And, ﬁnally, new wound therapies have improved the
postoperative care for these patients.92
Any foot compartment affected by infection should be opened
quickly to reduce the compartmental pressure.93 Contrary to
previously held beliefs, fascial planes do not constrain the spread ofFigure 6. Postoperative view: X-ray shoinfection.94 Although unproven, MRI may play a role in planning
the surgical approach.85,95 Unfortunately, there is no classiﬁcation
that deﬁnes either the point at which surgery is absolutely
necessary, or when it is likely to produce a better outcome than
further medical therapy.96–98 It is now clear, however, that in most
cases ‘conservative’ surgery (i.e., resection of just the affected bone,
without amputation)96,99–101 or antibiotic therapy alone can treat
osteomyelitis successfully.
The optimal timing of surgery for DFI is not well deﬁned, but
prompt surgery, including revascularization when necessary, may
reduce the need for above-ankle amputations.102–104 The rate of
success, including avoiding lower extremity amputation, in DFIs,
depends on the approach taken by the treating surgeon,105 which
often reﬂects his or her experience and skills. When amputation iswing the bone that was removed.
Figure 7. Total healing of the wound.
I. Uc¸kay et al. / International Journal of Infectious Diseases 40 (2015) 81–91 87performed, both the vertical level of the limb/foot and the
horizontal anatomical involvement help determine wound heal-
ing. In a recent study of diabetic foot osteomyelitis cases that were
treated surgically, those involving the ﬁrst metatarsal joint were
less likely to heal than those in other locations, such as the lesser
toes.106 For patients with wet gangrene or sepsis, a two-stage
amputation (initial guillotine with later revision) may lead to
better primary stump healing than a one-stage procedure.107
Contrary to previous beliefs, soft tissue coverage by skin grafting or
ﬂaps is possible if needed, even in ischemic areas.108
6. Negative-pressure wound therapy
We now have wound healing devices that were not even
dreamed of 30 years ago. Negative-pressure wound therapy
(NPWT), introduced about 20 years ago, is now widely used for
accelerating wound healing. There are, however, few published
data on the usefulness of this method for treating infected soft
tissue or bone.109 A systematic review identiﬁed four randomized
trials of NPWT for diabetic foot wounds.110 While all, including a
multicenter study that enrolled 342 patients,111 found that
wounds treated with NPWT healed more rapidly than those
receiving conventional dressings, the quality of each of the studies
was weak and there was heterogeneity in the outcomes studied
and patients selected.112,113 A more recent meta-analysis of four
randomized trials in diabetic foot ulcers concluded that NPWT
results in more effective and faster wound healing and may reduce
potential infective complications.113 A Cochrane review identiﬁed
two large trials that reported superior ulcer healing results with
NPWT compared to moist dressing alone, but three other smaller
trials did not conﬁrm this ﬁnding. None of these trials dealt with
infection.114 NPWT can be combined with simultaneous wound
irrigation or the instillation of antiseptics or antibiotics to reduce
the ‘wound bed bioburden,’ but the effectiveness of these methods
for curing or preventing infection is as yet unclear.115 One case–
control study including 82 diabetic patients demonstrated a
signiﬁcantly shorter length of hospital stay and a reduced number
of surgical visits in patients treated with negative pressure therapy
with antimicrobial installation compared to negative pressure
therapy without installation.116 More trials are needed to better
understand what role this instillation technique may have in
treating DFI.
7. Off-loading
Off-loading pressure from an ulcer is critical to getting it to heal,
including those that are infected.117 This was, is, and will be thecornerstone of both treatment and secondary prevention. The
criterion standard method for off-loading – the total contact cast –
leads to ulcer healing in over 90% of cases and has been available
for decades.117 What is new is recognizing that the key to its
success is that it is non-removable, ensuring patient adherence.118
For patients with little or no foot deformity, prefabricated extra
depth footwear with a stiff rocker bottom walking sole is usually
sufﬁcient. Cases with a moderate deformity may require custom-
made shoes with custom-moulded, full-contact insoles. Off-
loading can be partial and surgical, e.g., performing a ﬂexor-
tenotomy in a patient with claw toes. An elective surgical approach
may be right when conservative therapy has failed to prevent
severe deformity or joint instability, or in the presence of
ulcerating hammer and claw toes.119
Clinicians should generally explain to the patient the beneﬁt of
off-loading, but a recent Cochrane analysis of patient education for
preventing diabetic foot ulcers found that it may positively
inﬂuence short-term results, but overall there is still insufﬁciently
robust evidence that limited education alone is effective in
achieving a signiﬁcant reduction in the incidence of foot ulceration
and amputation.120,121
8. Adjunctive treatments
8.1. Hyperbaric oxygen therapy
The value of hyperbaric oxygen therapy (HBOT) for DFI continues
to be hotly debated.8 A 2012 Cochrane systematic review concluded
that HBOT signiﬁcantly increased ulcer healing in the short term, but
not the long term; because of the ﬂawed trials, however, they were
not conﬁdent in the results.122 Some studies suggest that HBOT
facilitates wound healing and decreases rates of lower extremity
amputation in diabetic patients with a foot ulcer or postsurgical
amputation wound,123,124 but most experience is retrospective and
non-comparative.125 There are, however, no published data directly
related to the effect of HBOT on infectious aspects (either soft tissue
or bone) of the diabetic foot.126
8.2. Wound stimulating factors
Several studies have examined the value of granulocyte-colony
stimulating factors for treating DFI or ulcers. A Cochrane review
based on ﬁve randomized trials concluded that these treatments
did not increase infection remission, but may reduce the need for
surgical interventions, especially amputations, and the duration of
hospitalization.127 Well-designed studies of platelet-derived
growth factors128,129 and skin substitutes have not shown any
speciﬁc beneﬁt regarding resolution or prevention of infection.130
Likewise, a Cochrane review found no evidence of beneﬁt for
autologous platelet-rich plasma in the treatment of chronic
wounds.131
8.3. Stem cell therapy
In recent years there has been less research using growth factors
on diabetic foot wounds and more employing stem cells.132 Most of
the initial studies used angiogenic growth factors alone, but the
limited efﬁcacy prompted studies investigating the potential
beneﬁts of cell-based therapy.133,134 Studies on the local injection
of unselected bone marrow-derived (or peripheral blood-derived)
mononuclear cells in patients with severe peripheral arterial disease
provided encouraging results, but the treatment did not provide
complete revascularization, probably due to the limited delivery of
speciﬁc angiogenic cells in the mixed cell population.135 Later
studies found that autologous bone marrow cell transplantation in
ischemic diabetic foot ulcers increased leg perfusion and reduced
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have also reported encouraging results.136 One investigation of
adipose tissue-derived stem cell implantation in patients with
critical limb ischemia, some of whom were diabetic, demonstrated
considerable angioneogenesis.137 Other investigators have also
successfully harvested adipose tissue stem cells from the abdominal
subcutaneous fat.138 While stem cell therapy shows encouraging
results regarding angiogenesis, it currently has no proven direct
effect on infection.
9. Limb revascularization
Peripheral arterial disease is present in about 50% of patients
with a DFI, and it appears to be an independent risk factor for limb
loss.139 Revascularization of the foot in diabetic patients can now
be accomplished by either arterial bypass surgery or endovascular
interventions, with limited evidence to support selecting one
technique over the other. Available data suggest that patients with
a life-expectancy of more than 2 years and extensive stenoses have
superior outcomes with open surgery.140 However, using endo-
vascular angioplasty can reach the infragenicular region, which
was not possible until the most recent decade.141 While
revascularization may be crucial for a critically ischemic limb, it
probably has no directly beneﬁcial effect on infection, other than to
provide adequate perfusion to ensure the delivery of systemically
administered antibiotics.
10. Clinical pathways, guidelines, and bundle interventions
As noted above, there are now several evidence-based DFI
guidelines that have been shown to provide validated approaches
to optimize outcomes.20 All address the critical importance of
multidisciplinary teams,16 which have repeatedly been shown to
help avoid adverse outcomes in both inpatients and outpatients
with DFIs.142 The deployment of teams is, however, hampered by
several logistical problems: (1) it is often difﬁcult to bring team
members together outside of a ﬁxed meeting time; (2) the number
of patients requiring evaluation often requires more time than is
available for ﬁxed team meetings; (3) members of the team often
turnover; and (4) funding for team members’ time or for
administrative support is often lacking. A new concept to provide
the advantages of a multidisciplinary team while overcoming some
of the logistical problems is the use of a clinical pathway
(preferably accompanied by electronic order-sets).143 Clinical
pathways may uncover improper diagnostic or therapeutic
approaches, or bottlenecks in providing optimal care. Order-sets
provide a powerful tool to implement ‘bundles’ (multiple
simultaneous interventions) and to encourage and facilitate
optimal and evidence-based care.144 Although studies to date
have been limited to before-and-after designs, teams and order-
sets may help to optimize (and minimize) the use of antibiotic
agents, reduce costs, and prevent unnecessary amputations.142
11. Future research
Increasing antibiotic resistance has stimulated research addres-
sing various types of non-antibiotic treatment for DFIs. Among these,
photodynamic inactivation,145 bactericidal laser therapy,146 and
bacteriophages147 appear to show promise. Using telemedicine
diagnostic support in the home environment may also allow needed
foot assessment as well as expert consultative advice. Recently,
investigators have developed a photographic foot imaging device for
use in home monitoring for the early diagnosis of foot ulcers and pre-
ulcerative lesions in diabetic patients.148 Home monitoring of foot
temperatures by infrared thermometry, with modiﬁcation of
activity when the temperature is elevated, has been shown to bereduce foot ulceration in patients with diabetes.149 Infrared thermal
cameras may be useful to detect infections or to predict which
patients are at risk of future foot complications,150 including
infections.151 A study of 38 patients with a diabetic foot complica-
tion found that diagnosis based on the combination of photographic
and temperature sensing devices was both sensitive and speciﬁc,
with good intra-observer agreement.152 Likewise, a quantum dot-
based foot mapping system (utilizing a red dot to show the presence
of bacteria and a green one to show areas of accumulating
inﬂammation) may help to visualize infection and differentiate it
from sterile inﬂammation.153Finally, given the high recurrence rates
of neuropathic foot ulcers, helping patients to modify their walking
pattern, perhaps with feedback-based approaches, may prove
useful.154 Employing other forms of physical therapy and rehabili-
tation may also help improve the outcomes of DFI.155
12. Conclusions
DFIs are a common, complex, and costly problem that will
almost certainly increase in prevalence in the near future. Clinical
research over the past three decades has markedly increased our
understanding of the pathophysiology, diagnosis, and treatment of
both soft tissue and bone infections. The task now is to implement
available validated guidelines, to audit processes and outcomes, to
educate providers and patients, and to further advance research.
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Bullet points:
 Our understanding of the pathophysiology, diagnosis, and
treatment of diabetic foot infections has improved dramatically
in the past 30 years.
 The development and validation of guidelines on diabetic foot
infections have provided an evidence-based approach to their
management.
 We now better know factors that affect the causative pathogens
in diabetic foot infections, allowing improved empiric antibiotic
therapy.
 Technology has improved our ability to diagnose osteomyelitis of
the diabetic foot, and studies have clariﬁed the roles of antibiotic
and surgical treatment of this infection.
 Many new technologies are now under evaluation, but the basic
principles of properly diagnosing infection, obtaining a specimen
for culture, selecting and reﬁning antibiotic therapy, rapidly
undertaking the surgical interventions required, ensuring ade-
quate arterial perfusion, and off-loading pressure remain the
keys to good outcomes.
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